China’s focus on first or best-in-class oncology drugs and innovative R&D will position it well in 2026 and beyond.

On December 12, 2025, the US Food and Drug Administration approved Johnson & Johnson subsidiary Janssen Biotech’s Akeega (niraparib and abiraterone acetate with prednisone for adults with deleterious ...

The strategic partnership sees two separate financial deals for the pair of oncology assets. Rights to Kelun’s integrin ...

Acute myeloid leukemia (AML) is an aggressive cancer of the blood and bone marrow, characterized by rapid growth of abnormal white blood cells. As AML primarily affects older adults, the global rise ...

Just 10 years ago, there was virtually no biopharmaceutical industry in China. But now, almost all global big pharma ...

Wondering if AstraZeneca is still a buy after its big run, or if the easy money has already been made? This breakdown will walk you through whether the current share price still makes sense. The stock ...

[RISK DISCLAIMER] All opinions, news, analysis, prices or other information contained on this report is provided by analyst of Zhejiang Huarui Information Consulting Co., Ltd (CCFGroup) as general ...

China’s growing capabilities have drawn pharmaceutical multinationals to the country to either buy or co-develop innovative drugs. China’s share of out-licensing deals to the US and Europe has risen ...

CSPC Pharmaceutical Group Ltd. has obtained approval from China’s National Medical Products Administration (NMPA) to initiate clinical trials with the company’s selective 5-HT2A receptor agonist, ...

The upcoming Gaithersburg facility will join AstraZeneca's local operations, including this cell manufacturing facility in Rockville, which opened in May. Photo credit: Courtesy of AstraZeneca Global ...

Frederick, MD — Gov. Wes Moore on Friday announced that AstraZeneca will invest $2 billion to expand its operations in Maryland in what he described as the “single largest private investment in ...

DEVELOPMENTS FROM FREDERICK. THE INVESTMENT PROVIDES AN ECONOMIC SHOT IN THE ARM, CREATES JOBS AND BOOSTS THE STATE’S EFFORT TO EXPAND MARYLAND’S LIFE SCIENCES SECTOR. TODAY IS ABOUT SHOWING THAT WE ...